SHANGHAI, Dec. 31, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, today announced the completion of $75 million (~500 million RMB) series C financing. This round of financing is led by...